摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(tert-butoxycarbonyl)-2-(1-hydroxy-butyl)-3,5-diphenyl-[1,4]-oxazine | 1233518-35-8

中文名称
——
中文别名
——
英文名称
4-(tert-butoxycarbonyl)-2-(1-hydroxy-butyl)-3,5-diphenyl-[1,4]-oxazine
英文别名
Tert-butyl 2-(1-hydroxybutyl)-3,5-diphenyl-1,4-oxazine-4-carboxylate;tert-butyl 2-(1-hydroxybutyl)-3,5-diphenyl-1,4-oxazine-4-carboxylate
4-(tert-butoxycarbonyl)-2-(1-hydroxy-butyl)-3,5-diphenyl-[1,4]-oxazine化学式
CAS
1233518-35-8
化学式
C25H29NO4
mdl
——
分子量
407.51
InChiKey
KXASNIWUPMJKLZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.7
  • 重原子数:
    30
  • 可旋转键数:
    7
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.32
  • 拓扑面积:
    59
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1,1-二甲氧基-N,N-二甲基乙胺4-(tert-butoxycarbonyl)-2-(1-hydroxy-butyl)-3,5-diphenyl-[1,4]-oxazine 以 xylenes 为溶剂, 反应 0.75h, 以70%的产率得到4-(tert-butoxycarbonyl)-2-butylidene-3-(dimethylcarbamoylmethyl)-3,5-diphenyl-2,3-dihydro-[1,4]-oxazine
    参考文献:
    名称:
    Access to novel bicyclic fused γ-butyrolactone using [3,3]-sigmatropic rearrangement and acid-lactonization sequence as key transformation
    摘要:
    In this Letter, we wish to disclose a new strategy for the construction of substituted gamma-butyrolactones. The latter might not only be of potential interest in terms of biological activity and synthesis but also allow access to original heterocyclic scaffolds. According to previous study, efficient two-step sequence involving Eschenmoser-Claisen rearrangement and acid-lactonization reaction was successfully applied for the construction of original fused bicyclic gamma-butyrolactones based on an 1.4-oxazine core. (C) 2010 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.tetlet.2010.04.041
  • 作为产物:
    描述:
    4-(tert-butoxycarbonyl)-3,5-diphenyl-4H-[1,4]oxazine 、 正丁醛正丁基锂六甲基磷酰三胺 作用下, 以 四氢呋喃正己烷 为溶剂, 反应 2.5h, 以89%的产率得到4-(tert-butoxycarbonyl)-2-(1-hydroxy-butyl)-3,5-diphenyl-[1,4]-oxazine
    参考文献:
    名称:
    Access to novel bicyclic fused γ-butyrolactone using [3,3]-sigmatropic rearrangement and acid-lactonization sequence as key transformation
    摘要:
    In this Letter, we wish to disclose a new strategy for the construction of substituted gamma-butyrolactones. The latter might not only be of potential interest in terms of biological activity and synthesis but also allow access to original heterocyclic scaffolds. According to previous study, efficient two-step sequence involving Eschenmoser-Claisen rearrangement and acid-lactonization reaction was successfully applied for the construction of original fused bicyclic gamma-butyrolactones based on an 1.4-oxazine core. (C) 2010 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.tetlet.2010.04.041
点击查看最新优质反应信息

文献信息

  • Access to novel bicyclic fused γ-butyrolactone using [3,3]-sigmatropic rearrangement and acid-lactonization sequence as key transformation
    作者:Elise Claveau、Erwan Noirjean、Pascal Bouyssou、Gérard Coudert、Isabelle Gillaizeau
    DOI:10.1016/j.tetlet.2010.04.041
    日期:2010.6
    In this Letter, we wish to disclose a new strategy for the construction of substituted gamma-butyrolactones. The latter might not only be of potential interest in terms of biological activity and synthesis but also allow access to original heterocyclic scaffolds. According to previous study, efficient two-step sequence involving Eschenmoser-Claisen rearrangement and acid-lactonization reaction was successfully applied for the construction of original fused bicyclic gamma-butyrolactones based on an 1.4-oxazine core. (C) 2010 Elsevier Ltd. All rights reserved.
查看更多

同类化合物

乙基6H-1,2-恶嗪-3-羧酸酯 6-乙氧基-6H-1,2-恶嗪-3-甲醛 6-乙氧基-3-苯基-6H-1,2-恶嗪 5-甲氧基-3,6-二氢-2H-[1,4]恶嗪 5-乙氧基-3,6-二氢-2H-1,4-恶嗪 5,6-二氢-2H-1,4-恶嗪-3-胺 4H-1,4-恶嗪 3H-咪唑并[2,1-c][1,4]恶嗪 3-甲基-5-苯基-2H-1,4-恶嗪 3,5-二苯基-2H-1,4-恶嗪 3,5,5,6-四甲基-5,6-二氢-2H-1,4-恶嗪-2-酮 2H-[1,4]恶嗪并[3,4-b][1,3]恶嗪 2H-1,4-恶嗪 2H-1,4-噁嗪-2-酮,5,6-二氢-5-(1-甲基乙基)-3-苯基-,(S)- 2H-1,4-噁嗪-2-酮,3-(1,1-二甲基乙基)-5,6-二氢-5-苯基-,(R)- 2H-1,3-恶嗪 2H-1,2-恶嗪 2-(二甲基氨基)-4-苯基-4H-1,3-恶嗪-5-甲醛 (5S)-5,6-二氢-6,6-二甲基-5-苯基-2H-1,4-恶嗪-2-酮 6-amino-4-phenyl-4H-1,2-oxazine-3,5-dicarbonitrile (2S,5R)-2-hydroxy-5,6-dihydro-2-ethyl-3-methyl-5-phenyl-2H-1,4-oxazine (2S,5R)-2-hydroxy-5,6-dihydro-3-methyl-2,5-diphenyl-2H-1,4-oxazine (2S,5R,6R)-2-hydroxy-5,6-dihydro-2,3-diethyl-5-methyl-6-phenyl-2H-1,4-oxazine (2S,5R)-2-hydroxy-5,6-dihydro-2,3-diethyl-5-phenyl-2H-1,4-oxazine (2S,5S,6R)-2-hydroxy-5,6-dihydro-2,3,5-trimethyl-6-phenyl-2H-1,4-oxazine (2S,5S,6R)-2-hydroxy-5,6-dihydro-2,3-diethyl-5-methyl-6-phenyl-2H-1,4-oxazine (2S,5S,6R)-2-hydroxy-5,6-dihydro-3,5-dimethyl-6-phenyl-2-propyl-2H-1,4-oxazine (Z)-methyl-2-((R)-5-(2-(methylthio)ethyl)-3-oxomorpholin-2-ylidene)acetate (Z)-methyl-2-((R)-5-benzyl-3-oxomorpholin-2-ylidene)acetate (2R,5R,6S)-5,6-dihydro-3,6-diphenyl-2-hydroxy-5-methyl-1,4-oxazine (2S,5R,6R)-2-hydroxy-5,6-dihydro-2-ethyl-3,5-dimethyl-6-phenyl-2H-1,4-oxazine (2S,5S,6R)-2-hydroxy-5,6-dihydro-2-ethyl-3,5-dimethyl-6-phenyl-2H-1,4-oxazine 2-heptafluoropropyl-3-trifluoromethyl-5,6-dihydro-1,4-oxazin-2-ol (2S,5R,6R)-2-hydroxy-5,6-dihydro-3,5-dimethyl-2,6-diphenyl-2H-1,4-oxazine (2S,5S,6R)-2-hydroxy-5,6-dihydro-3,5-dimethyl-2,6-diphenyl-2H-1,4-oxazine 6H-1,2-Oxazine 4,4,6-Trimethyl-2-dimethylamino-4H-1,3-oxazine 3-(chloromethyl)-5,6-dihydro-5,5-dimethyl-1,4-oxazin-2-one 3-(acetoxymethyl)-5,6-dihydro-5,5-dimethyl-1,4-oxazin-2-one 6-Butyl-2,4-diphenyl-4H-[1,3]oxazine 2-methyl-2,4,6-triphenyl-2H-1,3-oxazine (S)-2,4,6-triphenyl-4H-1,3-oxazine 2-Isopropenyl-6-phenyl-6-piperidin-1-yl-6H-[1,3]oxazin-4-ol 5-methyl-6-perhydroxy-3-phenyl-6H-1,2-oxazine 5-methyl-3-phenyl-6-(prop-2-yn-1-oxy)-6H-1,2-oxazine 2,2,3,3,6,6-Hexafluoro-5-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-3,6-dihydro-2H-[1,4]oxazine 4,4-Dimethyl-2-phenyl-1,3-oxazine (R)-3-(but-3-enyl)-5-phenyl-5,6-dihydro-2H-1,4-oxazin-2-one Acetic acid 3,5-dimethyl-6-oxo-3,6-dihydro-2H-[1,4]oxazin-3-ylmethyl ester (2R,5R)-3-methyl-5-phenyl-2-(trifluoromethyl)-5,6-dihydro-2H-1,4-oxazin-2-ol